Sagimet Biosciences (SGMT) Cash from Financing Activities (2022 - 2025)

Sagimet Biosciences' Cash from Financing Activities history runs 4 years deep, the most recent figure standing at $274000.0 for Q3 2025.

• In Q3 2025, Cash from Financing Activities changed N/A year-over-year to $274000.0; the TTM figure through Dec 2025 stood at $274000.0 (down 99.74% YoY), while the FY2025 annual figure was $275000.0, down 99.74% from the prior year.
• Cash from Financing Activities was $274000.0 for Q3 2025 at Sagimet Biosciences, up from -$27000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $104.8 million in Q1 2024 to a low of -$910000.0 in Q2 2023.
• Historically, Cash from Financing Activities has averaged $27.3 million across 4 years, with a median of -$27000.0 in 2024.
• Biggest YoY gain for Cash from Financing Activities was 77192.65% in 2024; the steepest drop was 97.03% in 2024.
• A 4-year view of Cash from Financing Activities shows it stood at -$55000.0 in 2022, then jumped by 158669.09% to $87.2 million in 2023, then sank by 100.03% to -$27000.0 in 2024, then soared by 1114.81% to $274000.0 in 2025.
• The last three Cash from Financing Activities figures came in at $274000.0 (Q3 2025), -$27000.0 (Q2 2024), and $104.8 million (Q1 2024), per Business Quant data.